EE644 Budget Impact Analysis of Axitinib (Caxetib®) as Second-Line Therapy for the Treatment of Metastatic Renal Cell Carcinoma in a Cohort in Mexico
Abstract
Authors
Paladio Hernández JÁ C Dominguez P Sanchez I Mercado I Monteon